Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03150914 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

Study acronym: MILED
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 24, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Study sites: 10 to 8v10 Show 1 more changeShow less
    • Study sites: 10 to 8
  2. Primary and study completion dates: Jun 30, 2024 to Jun 30, 2025 Site details revised at 1 of 10 sitesv9 Show 1 more changeShow less
    • Site details revised at 1 of 10 sites
  3. Primary and study completion dates: Jun 30, 2023 to Jun 30, 2024 Site details revised at 5 of 10 sitesv8 Show 1 more changeShow less
    • Site details revised at 5 of 10 sites
  4. Eligibility criteria expanded, about 15 words Site contacts updated at 1 of 10 sitesv7 Show 1 more changeShow less
    • Site contacts updated at 1 of 10 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Jun 6, 2021 to Jun 30, 2023 Study sites: 8 to 10 · Completion date: Jun 6, 2023 to Jun 30, 2023v6 Show 2 more changesShow less
    • Study sites: 8 to 10
    • Completion date: Jun 6, 2023 to Jun 30, 2023
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 9 to 8v5
  2. Study sites: 11 to 9v4
  3. Primary completion date: Jun 6, 2020 to Jun 6, 2021 Completion date: Jun 6, 2021 to Jun 6, 2023 · Site details revised at 6 of 11 sites · Eligibility criteria shortened, about 5 wordsv3 Show 3 more changesShow less
    • Completion date: Jun 6, 2021 to Jun 6, 2023
    • Site details revised at 6 of 11 sites
    • Eligibility criteria shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 6, 2017 to Jan 1, 2018 · Site details revised at 11 of 11 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Jun 6, 2017 to Jan 1, 2018
    • Site details revised at 11 of 11 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
Trial Details
NCT Number NCT03150914
Lead Sponsor University of Cincinnati
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS), The LAM Foundation
Conditions LAM, Lymphangioleiomyomatosis
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov